Table 1. Baseline demographics.
| Parameter | Number (%) |
|---|---|
|
Sex | |
| Male | 87 (51) |
| Female | 85 (49) |
|
Age (median 60) | |
| <60 | 83 (48) |
| ⩾60 | 89 (52) |
|
ECOG PS | |
| 0 | 27 (16) |
| 1 | 137 (80) |
| 2 | 8 (5) |
|
Metastases | |
| 1 | 63 (37) |
| 2 | 55 (32) |
| 3+ | 54 (31) |
|
Sites of metastases | |
| Lung | 100 (58) |
| Liver | 65 (38) |
| Bone | 48 (28) |
| Brain | 14 (8) |
|
Baseline LDH (U l−1), reference range (313–618 U l−1) | |
| <618 | 115 (67) |
| ⩾618 | 57 (33) |
|
Baseline ANC (K μl−1), reference range (1.7–7.3K μl−1) | |
| Normal (1.7–7.3) | 152 (88) |
| Elevated (⩾7.3) | 20 (12) |
|
Baseline ALC (K μl−1), reference range (1.2–4.8 K μl−1) | |
| Normal (1.2–4.8) | 76 (44) |
| Low (<1.2) | 96 (56) |
Abbreviations: ALC=absolute lymphocyte count; ANC=absolute neutrophil count; ECOG PS=Eastern Cooperative Group performance status; LDH=lactate dehydrogenase.
Baseline demographics of patients treated on phase 1 immune checkpoint inhibitor therapy. Sex, age, ECOG PS, number of metastases, sites of metastases, baseline LDH, baseline ANC, and baseline ALC are all listed.